Electronic Resource
Cost-Effectiveness of Single Versus Multifraction SABR for Pulmonary Oligometastases: The SAFRON II Trial.
| العنوان: | Cost-Effectiveness of Single Versus Multifraction SABR for Pulmonary Oligometastases: The SAFRON II Trial. |
|---|---|
| المؤلفون: | Lourenco, RDA, Khoo, T, Crothers, A, Haas, M, Montgomery, R, Ball, D, Bressel, M, Siva, S |
| بيانات النشر: | Elsevier 2022-12-01 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | PURPOSE: The use of stereotactic ablative body radiation therapy (SABR) in advanced cancer care is increasing, yet the cost-effectiveness of single-fraction (SF) versus multifraction (MF) SABR in pulmonary oligometastases is unknown. METHODS: A prespecified cost-effectiveness analysis was conducted of the Trans Tasman Radiation Oncology Group 13.01 - SAFRON II - randomized trial comparing SF with MF SABR in 87 patients with 133 pulmonary oligometastases. A partitioned survival model assessed costs and quality-adjusted life-years (QALY) over the within-trial period (4 years) and longer-term (10 years). Costs reflected a societal perspective, expressed in Australian dollars (A$) using 2020 prices and were estimated using patient level data on health care utilization for radiation therapy (including patient time), post-radiation systemic therapy and treatment of adverse effects. Quality of life was assessed using the EuroQoL EQ-5D-5L. The incremental cost-effectiveness ratio (ICER) was expressed as the cost per QALY gained for SF versus MF SABR, with uncertainty assessed using deterministic and probabilistic sensitivity analyses. RESULTS: SF cost less than MF for initial therapy (difference of A$1194/patient). Mean time to initiation of systemic drug therapy did not differ between arms (P = .94). Numerical differences in survival favoring SF resulted in greater overall health care use for the within-trial period. The within-trial ICER was A$15,821/QALY and A$23,265/QALY over the longer term. Results were most sensitive to the cost of postprogression therapies and utility values. The sensitivity analysis indicated that SF SABR has a 97% probability of being cost-effective at a willingness-to-pay of A$50,000/QALY. CONCLUSIONS: SF has lower initial costs and is highly likely to be cost-effective. Time to initiation of systemic therapy associated with disease progression is highly patient relevant and is a major driver of cost-effectiveness. Comparisons for SF SABR with no |
| مصطلحات الفهرس: | 0299 Other Physical Sciences, 1103 Clinical Sciences, 1112 Oncology and Carcinogenesis, Journal Article |
| URL: | Int J Radiat Oncol Biol Phys 10.1016/j.ijrobp.2022.01.024 |
| الاتاحة: | Open access content. Open access content info:eu-repo/semantics/closedAccess |
| Other Numbers: | LT1 oai:opus.lib.uts.edu.au:10453/169711 Int J Radiat Oncol Biol Phys, 2022, 114, (5), pp. 968-976 0360-3016 1879-355X 1382629052 |
| المصدر المساهم: | UNIV OF TECH, SYDNEY From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1382629052 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |